For other small molecules predicted by DrugBAN, those with high binding probabilities to MIP1b, TRAIL, and SCGFb and with structural similarities to drugs already approved for RA treatment were considered potential candidates for further investigation. This evidence concerns the gene CCL4 and rheumatoid arthritis.